Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors.
Biochem Pharmacol. 1999 Jun 15;57(12):1375-82. doi: 10.1016/s0006-2952(99)00062-3.
Biochem Pharmacol. 1999.
PMID: 10353258
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Hughes B, Howat D, Lisle H, Holbrook M, James T, Gozzard N, Blease K, Hughes P, Kingaby R, Warrellow G, Alexander R, Head J, Boyd E, Eaton M, Perry M, Wales M, Smith B, Owens R, Catterall C, Lumb S, Russell A, Allen R, Merriman M, Bloxham D, Higgs G.
Hughes B, et al.
Br J Pharmacol. 1996 Jul;118(5):1183-91. doi: 10.1111/j.1476-5381.1996.tb15522.x.
Br J Pharmacol. 1996.
PMID: 8818342
Free PMC article.
Item in Clipboard
CDP840: a novel inhibitor of PDE-4.
Perry MJ, O'Connell J, Walker C, Crabbe T, Baldock D, Russell A, Lumb S, Huang Z, Howat D, Allen R, Merriman M, Walls J, Daniel T, Hughes B, Laliberte F, Higgs GA, Owens RJ.
Perry MJ, et al.
Cell Biochem Biophys. 1998;29(1-2):113-32. doi: 10.1007/BF02737831.
Cell Biochem Biophys. 1998.
PMID: 9631241
Item in Clipboard
Fused thiophene derivatives as MEK inhibitors.
Laing VE, Brookings DC, Carbery RJ, Simorte JG, Hutchings MC, Langham BJ, Lowe MA, Allen RA, Fetterman JR, Turner J, Meier C, Kennedy J, Merriman M.
Laing VE, et al.
Bioorg Med Chem Lett. 2012 Jan 1;22(1):472-5. doi: 10.1016/j.bmcl.2011.10.105. Epub 2011 Nov 6.
Bioorg Med Chem Lett. 2012.
PMID: 22119475
Item in Clipboard
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R.
Jamieson D, et al.
Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28.
Eur J Cancer. 2016.
PMID: 27693888
Clinical Trial.
Item in Clipboard
Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ.
Allen RA, Brookings DC, Powell MJ, Delgado J, Shuttleworth LK, Merriman M, Fahy IJ, Tewari R, Silva JP, Healy LJ, Davies GCG, Twomey B, Cutler RM, Kotian A, Crosby A, McCluskey G, Watt GF, Payne A.
Allen RA, et al.
J Pharmacol Exp Ther. 2017 Jun;361(3):429-440. doi: 10.1124/jpet.116.237347. Epub 2017 Apr 25.
J Pharmacol Exp Ther. 2017.
PMID: 28442583
Item in Clipboard
4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase.
Alexander R, Balasundaram A, Batchelor M, Brookings D, Crépy K, Crabbe T, Deltent MF, Driessens F, Gill A, Harris S, Hutchinson G, Kulisa C, Merriman M, Mistry P, Parton T, Turner J, Whitcombe I, Wright S.
Alexander R, et al.
Bioorg Med Chem Lett. 2008 Aug 1;18(15):4316-20. doi: 10.1016/j.bmcl.2008.06.076. Epub 2008 Jun 28.
Bioorg Med Chem Lett. 2008.
PMID: 18625552
Item in Clipboard
An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.
Vugler A, O'Connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, Verbitsky A, Ying X, Rehberg M, Carrington B, Merriman M, Moss A, Nicholas JM, Stanley P, Wright S, Bourne T, Foricher Y, Brookings D, Horsley H, Herrmann M, Rao S, Kohlmann M, Florian P.
Vugler A, et al.
Front Pharmacol. 2022 Nov 16;13:1037983. doi: 10.3389/fphar.2022.1037983. eCollection 2022.
Front Pharmacol. 2022.
PMID: 36467083
Free PMC article.
Item in Clipboard
Cite
Cite